Login / Signup

P32-specific CAR T cells with dual antitumor and antiangiogenic therapeutic potential in gliomas.

Liat Rousso-NooriIgnacio MastandreaShauli TalmorTova WaksAnat Globerson LevinMaarja HaugasTambet TeesaluLuis Alvarez-VallinaZelig EshharDinorah Friedmann-Morvinski
Published in: Nature communications (2021)
Glioblastoma is considered one of the most aggressive malignancies in adult and pediatric patients. Despite decades of research no curative treatment is available and it thus remains associated with a very dismal prognosis. Although recent pre-clinical and clinical studies have demonstrated the feasibility of chimeric antigen receptors (CAR) T cell immunotherapeutic approach in glioblastoma, tumor heterogeneity and antigen loss remain among one of the most important challenges to be addressed. In this study, we identify p32/gC1qR/HABP/C1qBP to be specifically expressed on the surface of glioma cells, making it a suitable tumor associated antigen for redirected CAR T cell therapy. We generate p32 CAR T cells and find them to recognize and specifically eliminate p32 expressing glioma cells and tumor derived endothelial cells in vitro and to control tumor growth in orthotopic syngeneic and xenograft mouse models. Thus, p32 CAR T cells may serve as a therapeutic option for glioblastoma patients.
Keyphrases